 Edward Dempsey
Concepts (333)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neprilysin | 6 | 2017 | 47 | 2.400 |
Why?
| | Muscle, Smooth, Vascular | 22 | 2017 | 409 | 2.310 |
Why?
| | Pulmonary Artery | 26 | 2020 | 1024 | 1.820 |
Why?
| | Protein Kinase C | 15 | 2007 | 271 | 1.800 |
Why?
| | Hypoxia | 18 | 2021 | 956 | 1.340 |
Why?
| | rho GTP-Binding Proteins | 2 | 2020 | 61 | 1.220 |
Why?
| | Pulmonary Circulation | 7 | 2009 | 407 | 0.970 |
Why?
| | Isoenzymes | 9 | 2007 | 283 | 0.730 |
Why?
| | Hypertension, Pulmonary | 12 | 2021 | 1736 | 0.720 |
Why?
| | Lung | 11 | 2021 | 3521 | 0.700 |
Why?
| | Evans Blue | 1 | 2018 | 6 | 0.620 |
Why?
| | Capillary Permeability | 1 | 2018 | 137 | 0.590 |
Why?
| | Cell Division | 25 | 2009 | 754 | 0.570 |
Why?
| | Protein Kinase C-epsilon | 3 | 2005 | 27 | 0.560 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2019 | 236 | 0.540 |
Why?
| | Muscle Proteins | 1 | 2017 | 210 | 0.520 |
Why?
| | Blood Vessels | 3 | 2016 | 179 | 0.500 |
Why?
| | Endothelium, Vascular | 2 | 2020 | 830 | 0.440 |
Why?
| | Aging | 4 | 2020 | 1611 | 0.440 |
Why?
| | Animals | 44 | 2021 | 31565 | 0.430 |
Why?
| | Mice, Knockout | 6 | 2017 | 2562 | 0.430 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2013 | 25 | 0.420 |
Why?
| | Animals, Newborn | 10 | 2007 | 777 | 0.380 |
Why?
| | Airway Remodeling | 1 | 2010 | 57 | 0.350 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2017 | 907 | 0.340 |
Why?
| | Cattle | 16 | 2002 | 918 | 0.300 |
Why?
| | Mice | 14 | 2018 | 14843 | 0.290 |
Why?
| | Fibroblasts | 7 | 2019 | 834 | 0.290 |
Why?
| | Endothelin-1 | 2 | 2017 | 168 | 0.240 |
Why?
| | Signal Transduction | 7 | 2020 | 4501 | 0.240 |
Why?
| | Protein Kinases | 1 | 2007 | 304 | 0.240 |
Why?
| | Lung Neoplasms | 11 | 2012 | 2159 | 0.240 |
Why?
| | Enzyme Activation | 5 | 2017 | 771 | 0.220 |
Why?
| | rho-Associated Kinases | 2 | 2019 | 80 | 0.220 |
Why?
| | Cells, Cultured | 12 | 2017 | 3861 | 0.210 |
Why?
| | Lung Diseases | 2 | 2007 | 690 | 0.210 |
Why?
| | Mice, Inbred C57BL | 5 | 2017 | 4680 | 0.210 |
Why?
| | Vascular Remodeling | 2 | 2021 | 153 | 0.210 |
Why?
| | Insulin-Like Growth Factor I | 3 | 1997 | 286 | 0.210 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2002 | 48 | 0.200 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 3 | 2012 | 86 | 0.200 |
Why?
| | Cell Movement | 3 | 2017 | 863 | 0.190 |
Why?
| | Vasoconstriction | 1 | 2002 | 177 | 0.190 |
Why?
| | Growth Substances | 4 | 1997 | 138 | 0.190 |
Why?
| | Tetradecanoylphorbol Acetate | 5 | 1997 | 151 | 0.180 |
Why?
| | Butyrates | 1 | 2021 | 53 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2020 | 116 | 0.180 |
Why?
| | Phenotype | 5 | 2017 | 2784 | 0.180 |
Why?
| | Metabolic Diseases | 1 | 2021 | 98 | 0.180 |
Why?
| | Mitogens | 2 | 1997 | 58 | 0.170 |
Why?
| | Forkhead Box Protein O3 | 1 | 2020 | 13 | 0.170 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2021 | 186 | 0.170 |
Why?
| | Platelet-Derived Growth Factor | 3 | 1997 | 80 | 0.170 |
Why?
| | Vasa Vasorum | 1 | 2020 | 33 | 0.170 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2020 | 145 | 0.160 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2019 | 72 | 0.160 |
Why?
| | Genotype | 2 | 2017 | 1757 | 0.160 |
Why?
| | Cellular Microenvironment | 1 | 2019 | 77 | 0.160 |
Why?
| | Metabolome | 1 | 2021 | 274 | 0.160 |
Why?
| | Pulmonary Alveoli | 2 | 2012 | 372 | 0.150 |
Why?
| | Thymidine | 5 | 1996 | 58 | 0.150 |
Why?
| | ets-Domain Protein Elk-1 | 1 | 2017 | 13 | 0.150 |
Why?
| | Smooth Muscle Myosins | 1 | 2017 | 7 | 0.150 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2017 | 61 | 0.140 |
Why?
| | Actins | 3 | 2017 | 376 | 0.140 |
Why?
| | Microfilament Proteins | 1 | 2017 | 125 | 0.140 |
Why?
| | Vascular Diseases | 1 | 2019 | 233 | 0.130 |
Why?
| | Chronic Disease | 6 | 2009 | 1577 | 0.130 |
Why?
| | Calcium-Binding Proteins | 1 | 2017 | 205 | 0.130 |
Why?
| | Substance P | 1 | 2016 | 44 | 0.130 |
Why?
| | Doxycycline | 1 | 2016 | 54 | 0.130 |
Why?
| | Pneumonia | 1 | 2021 | 563 | 0.130 |
Why?
| | Duodenum | 1 | 2016 | 62 | 0.130 |
Why?
| | Neovascularization, Pathologic | 5 | 2020 | 280 | 0.130 |
Why?
| | Sleep Apnea Syndromes | 2 | 2013 | 74 | 0.120 |
Why?
| | Humans | 30 | 2021 | 114045 | 0.120 |
Why?
| | Uterus | 3 | 2006 | 191 | 0.120 |
Why?
| | Carcinogens | 2 | 2012 | 102 | 0.120 |
Why?
| | Myocardium | 1 | 2019 | 911 | 0.120 |
Why?
| | In Vitro Techniques | 5 | 2007 | 1003 | 0.120 |
Why?
| | Cell Communication | 1 | 1996 | 277 | 0.110 |
Why?
| | Sputum | 3 | 2005 | 286 | 0.110 |
Why?
| | Endothelial Cells | 3 | 2021 | 677 | 0.110 |
Why?
| | Estradiol | 2 | 1997 | 450 | 0.110 |
Why?
| | Enzyme Inhibitors | 4 | 2002 | 743 | 0.110 |
Why?
| | Cell Proliferation | 2 | 2017 | 2173 | 0.100 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 1997 | 801 | 0.100 |
Why?
| | Piperidines | 2 | 2012 | 159 | 0.100 |
Why?
| | Blotting, Western | 3 | 2012 | 1143 | 0.100 |
Why?
| | Quinazolines | 2 | 2012 | 240 | 0.100 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 2322 | 0.100 |
Why?
| | Bronchoscopy | 5 | 2009 | 196 | 0.090 |
Why?
| | Mice, Transgenic | 1 | 2016 | 1947 | 0.090 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2005 | 270 | 0.090 |
Why?
| | DNA Primers | 2 | 2009 | 508 | 0.090 |
Why?
| | Somatomedins | 1 | 1990 | 28 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 1726 | 0.090 |
Why?
| | Arteries | 2 | 2006 | 246 | 0.090 |
Why?
| | Carcinoma in Situ | 3 | 2005 | 44 | 0.090 |
Why?
| | Precancerous Conditions | 3 | 2004 | 155 | 0.090 |
Why?
| | Biomarkers | 1 | 2020 | 3397 | 0.080 |
Why?
| | Maleimides | 3 | 2000 | 23 | 0.080 |
Why?
| | Blood Pressure | 3 | 2021 | 1531 | 0.080 |
Why?
| | Isotretinoin | 1 | 2009 | 22 | 0.080 |
Why?
| | Tocopherols | 1 | 2009 | 22 | 0.080 |
Why?
| | ErbB Receptors | 1 | 2012 | 554 | 0.080 |
Why?
| | Cell Hypoxia | 3 | 1999 | 221 | 0.080 |
Why?
| | Biomarkers, Tumor | 3 | 2012 | 1032 | 0.080 |
Why?
| | Female | 17 | 2012 | 59324 | 0.080 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2005 | 577 | 0.070 |
Why?
| | Male | 10 | 2018 | 55396 | 0.070 |
Why?
| | Indoles | 3 | 2000 | 300 | 0.070 |
Why?
| | Bronchi | 2 | 2000 | 223 | 0.070 |
Why?
| | Galectin 1 | 1 | 2006 | 2 | 0.070 |
Why?
| | Heart Failure | 1 | 2019 | 1958 | 0.070 |
Why?
| | Genes, ras | 2 | 1997 | 91 | 0.070 |
Why?
| | Hyperoxia | 1 | 2007 | 99 | 0.070 |
Why?
| | Videotape Recording | 1 | 2006 | 30 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 3 | 2021 | 2182 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2013 | 3498 | 0.060 |
Why?
| | Thiazolidinediones | 1 | 2006 | 142 | 0.060 |
Why?
| | Smoking | 4 | 2009 | 1382 | 0.060 |
Why?
| | Rats | 4 | 2021 | 4913 | 0.060 |
Why?
| | DNA | 4 | 1997 | 1350 | 0.060 |
Why?
| | Hypertrophy, Right Ventricular | 2 | 2021 | 141 | 0.060 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2005 | 157 | 0.060 |
Why?
| | Blood | 2 | 1995 | 94 | 0.060 |
Why?
| | Calcium | 2 | 2002 | 1089 | 0.060 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2005 | 181 | 0.060 |
Why?
| | Endothelins | 2 | 1996 | 61 | 0.060 |
Why?
| | Drug Synergism | 3 | 1996 | 315 | 0.060 |
Why?
| | Drug Delivery Systems | 1 | 2007 | 295 | 0.060 |
Why?
| | Hemodynamics | 1 | 2009 | 1015 | 0.060 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 1997 | 580 | 0.060 |
Why?
| | Guinea Pigs | 3 | 2006 | 136 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2010 | 3003 | 0.050 |
Why?
| | Fetus | 2 | 1997 | 698 | 0.050 |
Why?
| | Stem Cells | 1 | 2007 | 541 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2005 | 388 | 0.050 |
Why?
| | Shaw Potassium Channels | 1 | 2002 | 4 | 0.050 |
Why?
| | Potassium Chloride | 1 | 2002 | 32 | 0.050 |
Why?
| | Potassium Channel Blockers | 1 | 2002 | 29 | 0.050 |
Why?
| | Angiotensin II | 1 | 2002 | 87 | 0.050 |
Why?
| | Potassium Channels | 1 | 2002 | 121 | 0.050 |
Why?
| | Nitric Oxide Synthase | 1 | 2002 | 209 | 0.050 |
Why?
| | Antineoplastic Agents | 2 | 2010 | 1875 | 0.050 |
Why?
| | Patient Education as Topic | 1 | 2006 | 666 | 0.050 |
Why?
| | Tunica Media | 2 | 1998 | 35 | 0.050 |
Why?
| | Urethane | 2 | 2012 | 41 | 0.050 |
Why?
| | Protein Kinase C beta | 2 | 2000 | 24 | 0.050 |
Why?
| | Macrophages | 2 | 2021 | 1259 | 0.050 |
Why?
| | Aged | 6 | 2010 | 18969 | 0.050 |
Why?
| | Gene Deletion | 1 | 2002 | 356 | 0.050 |
Why?
| | Systole | 1 | 2021 | 176 | 0.050 |
Why?
| | Fluorescence | 1 | 2001 | 148 | 0.050 |
Why?
| | Tight Junctions | 1 | 2021 | 68 | 0.050 |
Why?
| | Microvessels | 1 | 2021 | 66 | 0.050 |
Why?
| | Acetylation | 1 | 2021 | 209 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2009 | 2090 | 0.040 |
Why?
| | Nitric Oxide | 1 | 2005 | 817 | 0.040 |
Why?
| | Receptors, Purinergic P2Y | 1 | 2020 | 7 | 0.040 |
Why?
| | Cytokines | 2 | 2021 | 1824 | 0.040 |
Why?
| | Ligands | 1 | 2021 | 556 | 0.040 |
Why?
| | Neoplasms | 1 | 2013 | 2086 | 0.040 |
Why?
| | GTPase-Activating Proteins | 1 | 2019 | 72 | 0.040 |
Why?
| | Trans-Activators | 1 | 2001 | 366 | 0.040 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2019 | 55 | 0.040 |
Why?
| | Light | 1 | 2001 | 336 | 0.040 |
Why?
| | Up-Regulation | 1 | 2021 | 802 | 0.040 |
Why?
| | Oxygen | 1 | 2002 | 851 | 0.040 |
Why?
| | Leukocytes | 1 | 2019 | 272 | 0.040 |
Why?
| | Immune System | 1 | 2019 | 171 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2020 | 328 | 0.040 |
Why?
| | Middle Aged | 5 | 2010 | 26605 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2020 | 397 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2020 | 428 | 0.040 |
Why?
| | Aorta | 2 | 2001 | 388 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2019 | 316 | 0.040 |
Why?
| | Culture Media, Serum-Free | 1 | 1997 | 42 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 1997 | 33 | 0.040 |
Why?
| | Ischemia | 1 | 2000 | 361 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2020 | 359 | 0.030 |
Why?
| | Protein Kinase C-alpha | 1 | 1997 | 41 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2001 | 591 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2001 | 1690 | 0.030 |
Why?
| | Organ Specificity | 1 | 1997 | 266 | 0.030 |
Why?
| | Pregnancy, Animal | 1 | 1997 | 52 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 522 | 0.030 |
Why?
| | Muscle Development | 1 | 1997 | 99 | 0.030 |
Why?
| | Bronchial Neoplasms | 1 | 1996 | 13 | 0.030 |
Why?
| | Microcirculation | 2 | 2007 | 133 | 0.030 |
Why?
| | Heart Ventricles | 1 | 2021 | 723 | 0.030 |
Why?
| | Species Specificity | 1 | 1997 | 541 | 0.030 |
Why?
| | Rabbits | 1 | 1997 | 733 | 0.030 |
Why?
| | Point Mutation | 1 | 1997 | 216 | 0.030 |
Why?
| | Blood Physiological Phenomena | 1 | 1996 | 13 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2010 | 1836 | 0.030 |
Why?
| | Tritium | 1 | 1996 | 66 | 0.030 |
Why?
| | Receptors, Platelet-Derived Growth Factor | 1 | 1996 | 13 | 0.030 |
Why?
| | Neoplasms, Second Primary | 1 | 1997 | 92 | 0.030 |
Why?
| | Exercise | 1 | 2006 | 1642 | 0.030 |
Why?
| | Rats, Inbred Strains | 1 | 1996 | 360 | 0.030 |
Why?
| | Myocytes, Cardiac | 1 | 2019 | 449 | 0.030 |
Why?
| | Young Adult | 1 | 2010 | 10444 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 1996 | 373 | 0.030 |
Why?
| | Quality of Life | 1 | 2006 | 2343 | 0.030 |
Why?
| | Protein Precursors | 1 | 1996 | 119 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 926 | 0.030 |
Why?
| | Models, Biological | 1 | 2021 | 1611 | 0.030 |
Why?
| | Catalysis | 1 | 1995 | 289 | 0.030 |
Why?
| | Subcellular Fractions | 1 | 1994 | 77 | 0.030 |
Why?
| | Flow Cytometry | 2 | 1996 | 1075 | 0.030 |
Why?
| | Adenosine Diphosphate | 1 | 1994 | 76 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 1997 | 1228 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 1996 | 445 | 0.030 |
Why?
| | Blood Proteins | 1 | 1996 | 222 | 0.030 |
Why?
| | Poly I-C | 1 | 1994 | 51 | 0.030 |
Why?
| | Risk Factors | 5 | 2009 | 8614 | 0.030 |
Why?
| | Endothelin Receptor Antagonists | 1 | 1993 | 58 | 0.030 |
Why?
| | Hyperplasia | 2 | 2006 | 163 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 1996 | 385 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 1996 | 371 | 0.030 |
Why?
| | Extracellular Matrix | 2 | 2006 | 436 | 0.030 |
Why?
| | Complement Factor B | 1 | 1994 | 100 | 0.030 |
Why?
| | Serotonin | 1 | 1994 | 292 | 0.030 |
Why?
| | Methylcholanthrene | 1 | 2012 | 18 | 0.030 |
Why?
| | Adolescent | 1 | 2010 | 17800 | 0.030 |
Why?
| | Pregnancy | 3 | 2006 | 5499 | 0.030 |
Why?
| | Butylated Hydroxytoluene | 1 | 2012 | 31 | 0.030 |
Why?
| | Time Factors | 2 | 2007 | 6077 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 192 | 0.020 |
Why?
| | Peptides, Cyclic | 1 | 1993 | 252 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2007 | 5038 | 0.020 |
Why?
| | Blood Platelets | 1 | 1994 | 326 | 0.020 |
Why?
| | Apoptosis | 1 | 2000 | 2349 | 0.020 |
Why?
| | Cell Count | 2 | 2006 | 303 | 0.020 |
Why?
| | Phorbol 12,13-Dibutyrate | 1 | 1991 | 8 | 0.020 |
Why?
| | Aerobiosis | 1 | 1991 | 20 | 0.020 |
Why?
| | Anaerobiosis | 1 | 1991 | 48 | 0.020 |
Why?
| | Dimethyl Sulfoxide | 1 | 1991 | 42 | 0.020 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2012 | 167 | 0.020 |
Why?
| | Tumor Cells, Cultured | 3 | 1996 | 845 | 0.020 |
Why?
| | Protein Binding | 1 | 1996 | 1888 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2012 | 225 | 0.020 |
Why?
| | Chemoprevention | 1 | 2010 | 87 | 0.020 |
Why?
| | Biopsy | 2 | 2005 | 1024 | 0.020 |
Why?
| | DNA Replication | 1 | 1991 | 202 | 0.020 |
Why?
| | Antioxidants | 1 | 2012 | 529 | 0.020 |
Why?
| | RNA, Messenger | 1 | 1996 | 2550 | 0.020 |
Why?
| | Down-Regulation | 1 | 1990 | 594 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2010 | 347 | 0.020 |
Why?
| | Kinetics | 1 | 1991 | 1547 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2007 | 75 | 0.020 |
Why?
| | Rats, Inbred WKY | 1 | 2006 | 32 | 0.020 |
Why?
| | Elastin | 1 | 2006 | 78 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2006 | 63 | 0.020 |
Why?
| | Codon | 2 | 1997 | 85 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2009 | 6306 | 0.020 |
Why?
| | Serum | 1 | 2006 | 57 | 0.020 |
Why?
| | PPAR gamma | 1 | 2006 | 182 | 0.020 |
Why?
| | Vascular Resistance | 1 | 2006 | 340 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2006 | 492 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2010 | 784 | 0.010 |
Why?
| | Collagen | 1 | 2006 | 414 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2010 | 787 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1257 | 0.010 |
Why?
| | Sheep | 1 | 2006 | 761 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 850 | 0.010 |
Why?
| | Teaching | 1 | 2006 | 209 | 0.010 |
Why?
| | Polymerase Chain Reaction | 2 | 1997 | 990 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 2005 | 438 | 0.010 |
Why?
| | Epithelial Cells | 2 | 2001 | 946 | 0.010 |
Why?
| | Vital Capacity | 1 | 2004 | 254 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2004 | 302 | 0.010 |
Why?
| | Activities of Daily Living | 1 | 2006 | 348 | 0.010 |
Why?
| | Gestational Age | 1 | 2006 | 761 | 0.010 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2007 | 333 | 0.010 |
Why?
| | Forced Expiratory Volume | 1 | 2004 | 471 | 0.010 |
Why?
| | Base Sequence | 1 | 2006 | 2114 | 0.010 |
Why?
| | Patient Compliance | 1 | 2006 | 524 | 0.010 |
Why?
| | CREB-Binding Protein | 1 | 2001 | 27 | 0.010 |
Why?
| | Metaplasia | 1 | 2001 | 54 | 0.010 |
Why?
| | Adaptation, Psychological | 1 | 2006 | 545 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2001 | 259 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 1 | 2001 | 396 | 0.010 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2000 | 49 | 0.010 |
Why?
| | Loss of Heterozygosity | 1 | 2000 | 40 | 0.010 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2000 | 57 | 0.010 |
Why?
| | Fibrosis | 1 | 2002 | 452 | 0.010 |
Why?
| | Carcinoma | 1 | 2001 | 198 | 0.010 |
Why?
| | Ki-67 Antigen | 1 | 2000 | 102 | 0.010 |
Why?
| | Airway Obstruction | 1 | 2001 | 160 | 0.010 |
Why?
| | Prevalence | 1 | 2005 | 2247 | 0.010 |
Why?
| | Risk | 1 | 2001 | 810 | 0.010 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 1997 | 959 | 0.010 |
Why?
| | Cell Death | 1 | 2000 | 322 | 0.010 |
Why?
| | Mitotic Index | 1 | 1997 | 26 | 0.010 |
Why?
| | Bromodeoxyuridine | 1 | 1997 | 72 | 0.010 |
Why?
| | Mammals | 1 | 1999 | 241 | 0.010 |
Why?
| | Cytoskeletal Proteins | 1 | 1997 | 145 | 0.010 |
Why?
| | Tunica Intima | 1 | 1997 | 78 | 0.010 |
Why?
| | Myosins | 1 | 1997 | 125 | 0.010 |
Why?
| | Comorbidity | 1 | 2001 | 1447 | 0.010 |
Why?
| | Chromosome Banding | 1 | 1996 | 21 | 0.010 |
Why?
| | Ovariectomy | 1 | 1997 | 116 | 0.010 |
Why?
| | Ploidies | 1 | 1996 | 17 | 0.010 |
Why?
| | Karyotyping | 1 | 1996 | 100 | 0.010 |
Why?
| | Ligases | 1 | 1996 | 30 | 0.010 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2000 | 445 | 0.010 |
Why?
| | Heparin | 1 | 1997 | 225 | 0.010 |
Why?
| | Bronchoalveolar Lavage | 1 | 1996 | 82 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2000 | 1624 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2001 | 1310 | 0.010 |
Why?
| | Immunophenotyping | 1 | 1996 | 274 | 0.010 |
Why?
| | Regional Blood Flow | 1 | 1997 | 421 | 0.010 |
Why?
| | Mass Screening | 1 | 2001 | 979 | 0.010 |
Why?
| | HeLa Cells | 1 | 1996 | 563 | 0.010 |
Why?
| | Adult | 2 | 2009 | 30375 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2006 | 4595 | 0.010 |
Why?
| | Epidermal Growth Factor | 1 | 1994 | 160 | 0.010 |
Why?
| | Calcimycin | 1 | 1994 | 47 | 0.010 |
Why?
| | Prognosis | 1 | 2001 | 3315 | 0.010 |
Why?
| | Interferon-beta | 1 | 1994 | 79 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 1997 | 1162 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 1994 | 242 | 0.010 |
Why?
| | Cell Survival | 1 | 1996 | 1014 | 0.010 |
Why?
| | Macrophage Activation | 1 | 1994 | 163 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1993 | 1218 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1994 | 719 | 0.010 |
Why?
| | Mutation | 1 | 2000 | 3338 | 0.010 |
Why?
| | Peptides | 1 | 1994 | 847 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1994 | 1128 | 0.000 |
Why?
| | Retrospective Studies | 1 | 2005 | 12521 | 0.000 |
Why?
|
|
Dempsey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|